Abrezekimab (VR 942) is composed of CDP7766, leucine, and trehalose. Abrezekimab is a humanized antibody that targets human IL-13. Abrezekimab inhibits binding to IL-13Ralpha1 subunit. Abrezekimab can be used to study biological disorders associated with asthma and lung disease.
Purity:
98.34%
CAS Number:
[2043952-59-4]
Target:
IL Receptor|||Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted